Track Medifast, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Medifast, Inc. MED Open Medifast, Inc. in new tab

10.36 USD
P/E
535.50
EPS
-1.70
P/B
0.51
ROE
-9.13
Beta
0.58
Medifast, Inc. logo

Medifast, Inc.

🧾 Earnings Recap – Q3 2025

Medifast's third-quarter results for 2025 showcased a strategic shift towards a holistic approach to metabolic health, reinforcing its commitment to long-term wellness solutions while navigating changes in the weight loss industry.

  • Achieved 16-week clinical results showing clients retained 98% of lean mass and reduced visceral fat by 14%, underscoring the effectiveness of its metabolic health programs.
  • Expanded insights with 61% of coaches assisting clients using GLP-1 medications, highlighting the integration of medication knowledge into client support.
  • Announced plans for innovative product launches incorporating next-generation ingredients targeting metabolic enhancement, set to hit the market next year.
  • Transitioning brand perception from a weight loss company to a broader leader in metabolic health, targeting a more expansive and durable market.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateApril 27, 2026
P/E535.50
EPS-1.70
Book Value19.29
Price to Book0.51
Debt/Equity5.38
% Insiders3.203%
Growth
Revenue Growth-0.37%
Earnings Growth-0.95%
Estimates
Forward P/E-3.53
Forward EPS-2.76

DCF Valuation

Tweak assumptions to recompute fair value for Medifast, Inc. (MED)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Medifast, Inc. Logo Medifast, Inc. Analysis (MED)

United States Consumer Discretionary Official Website Stock

Is Medifast, Inc. a good investment? Medifast, Inc. (MED) is currently trading at 10.36 USD.

In terms of valuation, the stock trades at a P/E ratio of 535.50. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Medifast, Inc. is expected to release its next earnings report on April 27, 2026. The market consensus estimate for Forward EPS is -2.76.

Investor FAQ

Does Medifast, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Medifast, Inc.?

Medifast, Inc. is classified as a Stock. You can compare it against 5 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be April 27, 2026. The company currently has a trailing EPS of -1.70.

Company Profile

Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address weight loss in the United States. The company offers weight loss, weight management, and healthy living products comprising bars, cereals, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, soups, essential amino acid blends, whey protein, hot beverages, brownies, and mini meals under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories, as well as daily nutrient packs, including multivitamins, minerals, and omega-3 fatty acid supplements. It also provides lifestyle plans consisting of 5 & 1 Plan and 5 & 1 ACTIVE Plan, which provides a targeted reset of the body's metabolism by activating strong and targeted fat burn; Optimal Weight 4 & 2 & 1 Plan and Optimal Weight 4 & 2 ACTIVE Plan, which is designed for clients who want to continue eating all food groups or want a flexible meal plan to achieve a healthy weight; OPTAVIA Optimization Plan, a personalized approach to help clients' long-term weight management; and OPTAVIA GLP-1 Nutrition Support Plan, a nutritional companion to GLP-1 medication that allows clients to focus on weight loss without the stress of figuring out what to eat. In addition, the company offers metabolic synchronization, a science that reverses metabolic dysfunction through a targeted reset of the body's metabolism. It markets its products through point-of-sale transactions executed over an e-commerce platform. The company serves health and wellness consumers. The company was formerly known as Healthrite, Inc. and changed its name to Medifast, Inc. in May 2001. Medifast, Inc. was incorporated in 1980 and is headquartered in Baltimore, Maryland.

Exchange Ticker
LSE (United Kingdom) 0K05.L
MCE (Spain) MDF.MC
NYQ (United States) MED
FRA (Germany) MDF.F
MEX (Mexico) MED.MX
Historical Dividends
Year Total Dividends
2023 6.59 USD
2022 6.34 USD
2021 5.39 USD
2020 4.52 USD
2019 3.00 USD
2018 1.92 USD
2017 1.28 USD
2016 1.00 USD

Yearly aggregated dividends

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion